Skip to content

Risk Factors of Epistaxis Recurrence in Adults

Facteurs De Risques De Récidive D'épistaxis Chez L'adulte

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06657053
Acronym
FREA
Enrollment
145
Registered
2024-10-24
Start date
2024-11-02
Completion date
2025-04-01
Last updated
2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epistaxis

Keywords

Risk Factors, Recurrent Epistaxis

Brief summary

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied. The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.

Detailed description

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied : oral anticoagulants, sex, INR, anti-platelets drugs, diabetes, obesity, arterial hypertension, heart failure, hemoglobin at the admission, history of chronic rhinosinusitis, appointment with an ENT during the acute bleeding, sleep apnea, age, anatomic abnormality, recent surgery within 2 months, previous admission within 30 days in the emergency department, nasal trauma. The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test. This study aim to provide a pronostic score of recurrence that can happen after the 3 fisrt weeks after the event. When a recurrence happens before 3 weeks, this was considered to be a non control of the bleeding episode. This score will be then tested on our cohort to evaluate specificity and sensibility.

Interventions

None listed

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient who is admitted at the emergency department between 01/2022 and 07/2023 for nose bleeding. * Age over 18 yo

Exclusion criteria

* Opposition to be included * Patient who has not his willness to provide opposition to participate.opposition

Design outcomes

Primary

MeasureTime frameDescription
Survival without bleeding1 yearMeasuring the delay between the first epistaxis and a recurrence.

Countries

France

Contacts

Primary ContactAshley BAGUANT, Doctor
abaguant@chu-grenoble.fr+33476764522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026